- Trials with a EudraCT protocol (99)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
99 result(s) found for: Dust Mite.
Displaying page 1 of 5.
EudraCT Number: 2008-003879-49 | Sponsor Protocol Number: AB0802 | Start Date*: 2009-03-27 |
Sponsor Name:Artu Biologicals Europe B.V. | ||
Full Title: A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust ... | ||
Medical condition: Treatment of house dust mite induced allergic rhinoconjunctivitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002248-29 | Sponsor Protocol Number: AL1009ac | Start Date*: 2012-03-07 |
Sponsor Name:Allergopharma Joachim Ganzer KG | ||
Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of the optimal dose for safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed All... | ||
Medical condition: Controlled allergic bronchial asthma + rhinitis/rhinoconjunctivitis induced by house dust mite | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002844-18 | Sponsor Protocol Number: 04071962 | Start Date*: 2017-01-16 |
Sponsor Name:Medical University of Vienna, Dpt. of Pediatrics | ||
Full Title: Preventive sublingual immunotherapy for house dust mite sensitized preschool children | ||
Medical condition: Patients; children at age 4 years with house dust mite IgE sensitization without allergic disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003930-41 | Sponsor Protocol Number: DME_01 | Start Date*: 2007-11-20 |
Sponsor Name:Curalogic A/S | ||
Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated House Dust Mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) Extract (MHDME) in Subjects with House Dust Mite Allerg... | ||
Medical condition: Allergic rhinoconjunctivitis due to house mite dust allergy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002047-18 | Sponsor Protocol Number: SM/0044 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:HAL Allergy B.V. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis ... | |||||||||||||
Medical condition: Patients, 18-60 years of age, suffering from house dust mites-induced persistent allergic rhinitis/rhinoconjunctivitis with or without concomitant at least partly controlled asthma. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004583-30 | Sponsor Protocol Number: BIA-DPT-P2-001 | Start Date*: 2012-01-16 |
Sponsor Name:BIAL Industrial Farmaceutica | ||
Full Title: A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCT... | ||
Medical condition: Allergic rhinoconjunctivitis with or without associated asthma. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004639-39 | Sponsor Protocol Number: CYT003-QbG10 09 | Start Date*: 2008-10-03 | |||||||||||
Sponsor Name:Cytos Biotechnology AG | |||||||||||||
Full Title: Double-blind, Placebo-controlled Dose-finding Study with CYT003-QbG10 in Adult Patients with Rhinoconjunctivitis due to House Dust Mite Allergy. | |||||||||||||
Medical condition: Adult patients with perennial allergic rhinoconjunctivitis due to house dust mite | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) LV (Completed) LT (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000446-34 | Sponsor Protocol Number: MT-18 | Start Date*: 2020-07-14 | |||||||||||
Sponsor Name:ALK-Abelló A/S | |||||||||||||
Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic... | |||||||||||||
Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000820-27 | Sponsor Protocol Number: MM09-SIT-013 | Start Date*: 2016-02-16 | |||||||||||
Sponsor Name:Inmunotek, S.L. | |||||||||||||
Full Title: Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Derma... | |||||||||||||
Medical condition: Mites allergy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005534-12 | Sponsor Protocol Number: AVH-2004/1 | Start Date*: 2006-04-18 |
Sponsor Name:The Symbio Herborn Group GmbH | ||
Full Title: randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy | ||
Medical condition: Allergic diseases such as rhinoconjunctivitis or bronchial asthma are a major public health burden. The huge associated costs demand an evidence based therapeutic aproach. The only available causat... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003892-35 | Sponsor Protocol Number: AL 0104 av | Start Date*: 2005-04-01 |
Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG | ||
Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of... | ||
Medical condition: IgE-mediated allergic disease in adults and children manifested as bronchial asthma (GINA II and III) +/-allergic rhinitis/rhinoconjunctivitis, triggered by non-eliminable house dust mite allergens. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000557-13 | Sponsor Protocol Number: ABT-hdmASIT001 | Start Date*: 2016-08-10 | |||||||||||
Sponsor Name:ASIT biotech S.A. | |||||||||||||
Full Title: Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients. | |||||||||||||
Medical condition: Treatment of house dust mite induced allergic rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003454-29 | Sponsor Protocol Number: CYT005-AllQbG10 04 | Start Date*: 2007-10-19 | |||||||||||
Sponsor Name:Cytos Biotechnology AG | |||||||||||||
Full Title: Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immuotherapy Combining Allergen with CYT003-QbG10 (CYT005-AllQbG10) in... | |||||||||||||
Medical condition: Adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001795-20 | Sponsor Protocol Number: MT-02 | Start Date*: 2006-06-29 |
Sponsor Name:ALK-Abelló A/S | ||
Full Title: A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects | ||
Medical condition: IgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) DK (Completed) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000487-28 | Sponsor Protocol Number: VO72.12 | Start Date*: 2013-08-20 | ||||||||||||||||
Sponsor Name:STALLERGENES SA | ||||||||||||||||||
Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma | ||||||||||||||||||
Medical condition: house dust mite-associated allergic asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000934-11 | Sponsor Protocol Number: Al0106ac | Start Date*: 2006-08-11 |
Sponsor Name:Alllergopharma Joachim Ganzer KG | ||
Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparatio... | ||
Medical condition: IgE-mediated allergic disease in adults manifested as rhinitis/ rhinoconjunctivitis and/or allergic asthma bronchiale (GINA I and II) triggered by non eliminable house dust mite allergens. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003516-62 | Sponsor Protocol Number: CYT003-QbG10 08 | Start Date*: 2007-10-19 | |||||||||||
Sponsor Name:Cytos Biotechnology AG | |||||||||||||
Full Title: Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis. | |||||||||||||
Medical condition: Adult patients with perennial allergic rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007096-32 | Sponsor Protocol Number: PREV1234 | Start Date*: 2009-01-07 |
Sponsor Name:Medizinische Universität Wien, Univ. Kinderklinik | ||
Full Title: Prevention od new sensitization by sublingual immunotherapy in children 2-4 years of age with allergic mono-sensitization | ||
Medical condition: Children (2-4years of age) from atopy prone families with an allergic sensitization as defined by positive skin prick test or positive allergen-specific IgE to grass pollen or house dust mite aller... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004223-46 | Sponsor Protocol Number: SL75.14 | Start Date*: 2015-09-16 | |||||||||||
Sponsor Name:Stallergenes | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with ... | |||||||||||||
Medical condition: House dust mite allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SK (Completed) DE (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001454-77 | Sponsor Protocol Number: VO57.07 | Start Date*: 2007-09-12 | |||||||||||
Sponsor Name:Stallergenes S.A | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets o... | |||||||||||||
Medical condition: House dust mite allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.